Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Diverticular Disease Market Analysis

ID: MRFR/Pharma/4239-HCR
105 Pages
Vikita Thakur
April 2026

Diverticular Disease Market Research Report Information Type (Diverticulosis, Diverticulitis) Treatment (Medication, Supportive Care, Surgery) Diagnosis (CT Scan, Ultrasound, Urine Test, Blood Test) End User (Hospitals, Specialty Centers) – Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Diverticular Disease Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of Diverticular Disease Market Industry Landscape

Several market factors define the dynamics and growth trajectory of the Diverticular Disease Market, which different players within it collectively influence. One important driver of this market is the rise of Diverticulitis cases, especially among older adults (Diverticulitis Market - Global Industry Analysis, Size, Share, Growth Trends And Forecast 2013 – 2019). Medical research breakthroughs that occur over time play an important role in influencing how this market operates. More understanding of the pathophysiology of diverticulitis emanates from ongoing studies coupled with novel therapeutic initiatives being developed to address it accordingly (Ferzoco et al., 2008). This creates a larger market scope within which doctors can effectively manage such illnesses. The development and commercialization of treatments for diverticular disease largely depend on regulatory considerations. Complying with strict regulatory standards ensures the safety and effectiveness of these medications, hence instilling confidence in all parties involved. Economic factors highly affect the market for diverticular diseases. Economic growth and stability have contributed to better accessibility of treatments for diverticular disease due to an increase in healthcare spending (Kaiser Family Foundation, 2008). However, economic recessions may change priorities with respect to health expenditure, thereby affecting market dynamics. Diverticulitis should be affordable and accessible, given the dominance of certain economic factors that largely influence choices made with respect to healthcare in some regions. The competitive landscape between pharmaceutical and healthcare companies is a critical aspect that influences this market largely because intense competition brings about innovation as firms compete to create superior products, both regarding therapy and diagnosis tools meant for diverticulitis. The competitive landscape is shaped by strategic alliances, mergers, and acquisitions aimed at broadening product portfolios as well as expanding their customer base into the diverticulosis market segment (Diverticulitis Market - Global Industry Analysis, Size, Share, Growth Trends And Forecast 2013 – 2019). Also, changing consumer preferences and evolving healthcare trends impact Diverticulitis markets. This, together with reimbursement policies, affects how this market operates; thus, these companies target those whose price is insured or paid through insurance.

Author
Author Profile
Vikita Thakur
Senior Research Analyst

She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Diverticular Disease Market as of 2024?

The Diverticular Disease Market was valued at approximately 1660.26 USD Million in 2024.

What is the projected market valuation for the Diverticular Disease Market in 2035?

The market is projected to reach approximately 3832.62 USD Million by 2035.

What is the expected CAGR for the Diverticular Disease Market during the forecast period 2025 - 2035?

The expected CAGR for the Diverticular Disease Market during the forecast period 2025 - 2035 is 7.86%.

Which companies are considered key players in the Diverticular Disease Market?

Key players in the market include AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., Pfizer, Amgen, Gilead Sciences, Takeda Pharmaceutical, and AstraZeneca.

How is the Diverticular Disease Market segmented by disease type?

The market is segmented by disease type into Diverticulitis, Diverticulosis, and Diverticular Bleeding, with valuations ranging from 600.0 to 1800.0 USD Million.

What are the treatment types available in the Diverticular Disease Market?

Treatment types include Medication, Surgery, Dietary Management, and Lifestyle Changes, with valuations from 260.26 to 1400.0 USD Million.

How does patient demographics influence the Diverticular Disease Market?

The market is segmented by patient demographics, including Age Group, Gender, and Socioeconomic Status, with valuations between 560.26 and 1400.0 USD Million.

What is the market performance based on severity levels of diverticular disease?

The market performance by severity level includes Mild, Moderate, and Severe cases, with valuations ranging from 499.12 to 1500.0 USD Million.

How does the healthcare setting impact the Diverticular Disease Market?

The market is segmented by healthcare setting into Outpatient, Inpatient, and Emergency Care, with valuations from 502.05 to 1500.0 USD Million.

What trends are expected in the Diverticular Disease Market by 2035?

By 2035, the Diverticular Disease Market is expected to grow significantly, driven by advancements in treatment options and increasing awareness.

Market Summary

As per MRFR analysis, the Diverticular Disease Market Size was estimated at 1660.26 USD Million in 2024. The Diverticular Disease industry is projected to grow from 1809.78 in 2025 to 3832.62 by 2035, exhibiting a compound annual growth rate (CAGR) of 7.86% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Diverticular Disease Market is experiencing notable growth driven by increasing awareness and advancements in treatment options.

  • Rising awareness and education about diverticular disease are enhancing patient engagement and treatment adherence in North America.
  • Technological advancements in treatment are fostering innovative solutions, particularly in the Asia-Pacific region, which is witnessing rapid market expansion.
  • Demographic changes and lifestyle factors are contributing to the growing prevalence of diverticulitis, the largest segment in the market.
  • The increasing prevalence of diverticular disease and advancements in diagnostic techniques are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 1660.26 (USD Million)
2035 Market Size 3832.62 (USD Million)
CAGR (2025 - 2035) 7.86%
Largest Regional Market Share in 2024 North America

Major Players

AbbVie (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Merck & Co. (US), Pfizer (US), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (JP), AstraZeneca (GB)

Market Trends

The Diverticular Disease Market is currently experiencing notable transformations driven by various factors. Increasing awareness regarding gastrointestinal health has led to a rise in the diagnosis and treatment of diverticular disease. Healthcare providers are emphasizing preventive measures and early intervention, which appears to enhance patient outcomes. Furthermore, advancements in medical technology and treatment options are likely to contribute to the market's growth. Innovative therapies, including minimally invasive surgical techniques and novel pharmacological agents, are emerging, potentially improving the management of this condition. In addition, the demographic shift towards an aging population may further influence the Diverticular Disease Market. Older adults are more susceptible to developing diverticular disease, which could lead to a higher demand for healthcare services and interventions. Moreover, the increasing prevalence of lifestyle-related factors, such as poor diet and sedentary behavior, seems to correlate with the rising incidence of diverticular disease. As a result, stakeholders in the healthcare sector are likely to focus on developing targeted strategies to address these challenges, ultimately shaping the future landscape of the market.

Rising Awareness and Education

There is a growing emphasis on educating the public about diverticular disease and its implications. This trend is fostering a proactive approach to gastrointestinal health, encouraging individuals to seek medical advice and undergo screenings.

Technological Advancements in Treatment

Innovations in medical technology are transforming treatment options for diverticular disease. Minimally invasive procedures and new pharmacological therapies are becoming more prevalent, potentially enhancing patient recovery and outcomes.

Demographic Changes and Lifestyle Factors

The aging population and increasing prevalence of unhealthy lifestyles are contributing to a higher incidence of diverticular disease. This trend is likely to drive demand for healthcare services and interventions tailored to this demographic.

Diverticular Disease Market Market Drivers

Market Growth Projections

The Global Diverticular Disease Market Industry is projected to experience substantial growth over the next decade. With a market value of 1.83 USD Billion in 2024, it is anticipated to reach 3.94 USD Billion by 2035, reflecting a compound annual growth rate of 7.22% from 2025 to 2035. This growth trajectory indicates a robust demand for healthcare services and interventions related to diverticular disease. Factors contributing to this expansion include the rising prevalence of the disease, advancements in diagnostic and treatment options, and increased healthcare expenditure. Such projections highlight the importance of strategic planning and investment in the healthcare sector.

Rising Healthcare Expenditure

The Global Diverticular Disease Market Industry is positively impacted by the rising healthcare expenditure across various regions. Governments and private sectors are increasingly investing in healthcare infrastructure and services, which enhances access to treatment for diverticular disease. This trend is particularly evident in developed nations, where healthcare budgets are expanding to accommodate the growing burden of chronic diseases. As healthcare spending rises, it is anticipated that the market will experience robust growth, with a projected CAGR of 7.22% from 2025 to 2035. This financial commitment underscores the importance of addressing diverticular disease within broader healthcare strategies.

Growing Awareness and Education

Increasing awareness and education regarding diverticular disease are pivotal drivers of the Global Diverticular Disease Market Industry. Public health campaigns and educational initiatives have been instrumental in informing individuals about the risk factors and symptoms associated with the condition. This heightened awareness encourages early diagnosis and treatment, ultimately leading to better health outcomes. Healthcare professionals are also becoming more knowledgeable about the disease, which may contribute to improved patient management. As awareness continues to grow, the market is likely to see an uptick in demand for therapeutic options and preventive measures.

Advancements in Diagnostic Techniques

Technological innovations in diagnostic methods are significantly influencing the Global Diverticular Disease Market Industry. Enhanced imaging techniques, such as high-resolution CT scans and MRI, allow for more accurate detection and assessment of diverticular disease. These advancements facilitate timely diagnosis, which is crucial for effective management and treatment. As healthcare providers increasingly adopt these technologies, the market is expected to benefit from improved patient outcomes and reduced healthcare costs. The integration of artificial intelligence in diagnostics may further streamline processes, potentially increasing market growth as more patients receive appropriate care.

Rising Prevalence of Diverticular Disease

The Global Diverticular Disease Market Industry is experiencing a notable increase in prevalence, particularly among aging populations. As individuals age, the risk of developing diverticular disease escalates, leading to a higher demand for treatment options. In 2024, the market is projected to reach 1.83 USD Billion, reflecting the growing need for healthcare services and interventions. This trend is likely to continue as the global population ages, with estimates suggesting that by 2035, the market could expand to 3.94 USD Billion. Such growth underscores the importance of addressing diverticular disease in public health initiatives.

Increased Research and Development Activities

The Global Diverticular Disease Market Industry is witnessing a surge in research and development activities aimed at understanding the disease better and developing innovative treatment options. Pharmaceutical companies and research institutions are focusing on creating new therapies and improving existing ones, which could lead to more effective management of diverticular disease. This emphasis on R&D is likely to result in the introduction of novel medications and interventions, thereby expanding the market. As the understanding of diverticular disease evolves, it is expected that the market will continue to grow, driven by advancements in treatment methodologies.

Market Segment Insights

By Disease Type: Diverticulitis (Largest) vs. Diverticulosis (Fastest-Growing)

In the Diverticular Disease Market, Diverticulitis holds the largest market share among the three prominent disease types, reflecting its significant prevalence and the critical nature of its treatment. Contrarily, Diverticulosis, while historically less impactful, is rapidly increasing in recognition and market acceptance due to rising awareness and diagnosis rates. Diverticular Bleeding, although present, accounts for a smaller segment as it is less frequently diagnosed compared to the other two conditions. The growth trends within this segment are predominantly driven by an aging population, increased incidence of diverticular diseases, and advancements in diagnostic technologies. Additionally, shifts in dietary patterns and lifestyle choices are fostering a greater emphasis on early diagnosis and management. The rising investment in research and the development of targeted therapies further enhances the market growth for Diverticulitis and Diverticulosis, suggesting substantial future potential for these disease types.

Diverticulitis (Dominant) vs. Diverticular Bleeding (Emerging)

Diverticulitis represents the dominant segment in the Diverticular Disease Market, characterized by its higher incidence rate and severity compared to Diverticular Bleeding. Patients with Diverticulitis often experience significant discomfort and require more intensive management, leading to a robust market for treatments. Diverticulitis is primarily driven by dietary factors and sedentary lifestyles, making it a focal point for healthcare strategies. On the other hand, Diverticular Bleeding, though emerging as a notable condition, typically presents less frequently, resulting in lower market engagement. However, increasing awareness and diagnostic capabilities for diverticular issues are likely to propel its recognition in the market, providing opportunities for innovative treatment options to cater to this growing need.

By Treatment Type: Medication (Largest) vs. Surgery (Fastest-Growing)

The treatment type segment for diverticular disease consists of various approaches, including medication, surgery, dietary management, and lifestyle changes. Among these, medication remains the largest segment, providing patients with necessary relief from symptoms and preventing complications. Surgery, however, is rapidly gaining traction as a viable option, especially for those with severe cases, driving its growth in the market.

Medication (Dominant) vs. Surgery (Emerging)

Medication as a dominant segment in the diverticular disease treatment landscape focuses on pharmacological interventions to manage symptoms and prevent exacerbations. This includes anti-inflammatory drugs, <a href="https://www.marketresearchfuture.com/reports/antibiotics-market-8447" target="_blank" title="antibiotics">antibiotics</a>, and pain relief medications that cater to a wide range of patient needs. In contrast, surgery, categorized as an emerging option, is becoming increasingly relevant for individuals facing severe diverticular complications. Surgical interventions can resolve acute cases effectively, but their adoption involves careful consideration of risks and benefits, making it a growing area of interest for healthcare professionals and patients alike.

By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the market for Diverticular Disease, age demographics play a crucial role in shaping patient profiles, with older adults aged 50 and above representing the largest percentage of diagnoses. This age group accounts for a significant portion of the patient population, driven by factors such as increased prevalence of the disease with age and greater awareness of gastrointestinal health among older individuals. Additionally, gender also influences demographics, with a growing recognition of how the disease manifests differently between males and females, thus expanding the market's focus on both genders as critical segments.

Age Group: 50+ (Dominant) vs. Gender: Female (Emerging)

The age group of 50 years and above is the dominant demographic in the Diverticular Disease market, as this cohort exhibits the highest incidence rates of the condition, primarily due to age-related factors such as declining digestive health and lifestyle choices established over a lifetime. Conversely, the female gender is emerging as a significant segment in recent years, partially fueled by research indicating that women may experience different symptoms and complications associated with diverticular disease compared to men. This emerging trend is prompting healthcare providers and researchers to focus more on gender-specific treatment approaches and awareness programs.

By Severity Level: Moderate (Largest) vs. Severe (Fastest-Growing)

<p>The Diverticular Disease Market displays a distinct segmentation based on severity levels, where moderate cases dominate the market share compared to mild and severe cases. Mild cases, while prevalent, represent a smaller portion of the market due to lower healthcare interventions required. Conversely, moderate severity levels drive a significant portion of healthcare expenses and patient attention, underscoring their importance in healthcare strategies. Growth trends indicate that the severe segment is rapidly expanding, propelled by increasing awareness and advancements in medical technologies. The rise in diagnostic capabilities and treatment options for severe cases is contributing to this surge. Furthermore, demographics, including an aging population and changing dietary habits leading to serious forms of diverticular disease, are key drivers behind the acceleration of the severe segment.</p>

<p>Moderate (Dominant) vs. Severe (Emerging)</p>

<p>In the Diverticular Disease Market, the moderate severity level is seen as the dominant segment due to its significant patient population and healthcare demands. This segment encompasses a wide range of clinical presentations that necessitate regular monitoring and potential interventions, which increasingly captures the attention of healthcare providers. In contrast, the severe segment is emerging as a key player, fueled by increased diagnosis and the urgency of management associated with acute episodes. Patients classified as severe often experience more complex treatment regimens and require specialized care, resulting in heightened healthcare utilization. As awareness of diverticular disease grows, both segments are likely to see shifts in treatment protocols, further influencing their market trajectories.</p>

By Healthcare Setting: Outpatient (Largest) vs. Inpatient (Fastest-Growing)

<p>The healthcare setting segment in the diverticular disease market is characterized by three primary categories: Outpatient, Inpatient, and Emergency Care. Among these, the Outpatient setting holds the largest share due to the preference for less invasive treatment options and the increasing prevalence of diverticular disease, which allows for effective management in outpatient facilities. In contrast, Inpatient care is witnessing rapid growth, driven by the need for surgeries and advanced treatments for severe cases, as well as increasing healthcare costs and resource allocation for hospitalized patients needing immediate attention.</p>

<p>Outpatient (Dominant) vs. Inpatient (Emerging)</p>

<p>The Outpatient setting remains the dominant choice for managing diverticular disease due to its cost-effectiveness and convenience for patients. Patients prefer outpatient care because it minimizes disruptions to daily life, allowing for flexible scheduling and reduced recovery times. On the other hand, the Inpatient segment is classified as an emerging area, reflecting the shift towards managing more complicated cases in a hospital environment. Factors such as an aging population, increased rates of complications, and advancements in surgical techniques are amplifying the demand for inpatient care. As more patients present with severe diverticular disease, the inpatient setting will likely see continued growth, addressing complex cases that require surgical interventions and multidisciplinary approaches.</p>

Get more detailed insights about Diverticular Disease Market Research Report - Forecast to 2035

Regional Insights

North America : Market Leader in Healthcare

North America is poised to maintain its leadership in the Diverticular Disease market, holding a significant market share of 830.13 million in 2024. The region's growth is driven by increasing healthcare expenditure, advanced medical technologies, and a rising prevalence of diverticular disease among the aging population. Regulatory support and innovative treatment options further enhance market dynamics, making it a hub for pharmaceutical advancements. The competitive landscape in North America is robust, featuring key players such as AbbVie, Johnson & Johnson, and Merck & Co. These companies are at the forefront of research and development, focusing on novel therapies and patient-centric solutions. The U.S. remains the largest market, supported by favorable reimbursement policies and a strong emphasis on healthcare innovation, ensuring continued growth in this sector.

Europe : Emerging Market with Growth Potential

Europe's Diverticular Disease market is projected to grow significantly, with a market size of 550.09 million. The region benefits from a well-established healthcare system, increasing awareness of gastrointestinal disorders, and a growing elderly population. Regulatory frameworks are evolving to support innovative treatments, which is expected to drive demand and improve patient outcomes across member states. Leading countries such as Germany, France, and the UK are pivotal in this market, hosting major pharmaceutical companies like AstraZeneca and Bristol-Myers Squibb. The competitive landscape is characterized by a mix of established players and emerging biotech firms, all striving to address the unmet needs in diverticular disease management. This dynamic environment fosters innovation and collaboration, enhancing the overall market landscape.

Asia-Pacific : Rapidly Growing Healthcare Sector

The Asia-Pacific region is witnessing a burgeoning Diverticular Disease market, valued at 220.05 million. Factors such as increasing urbanization, dietary changes, and a rise in lifestyle-related diseases are driving demand for effective treatment options. Governments are also investing in healthcare infrastructure, which is expected to enhance access to medical services and improve patient outcomes in the region. Countries like Japan and Australia are leading the charge, with significant contributions from local pharmaceutical companies and multinational corporations. The competitive landscape is evolving, with key players like Takeda Pharmaceutical and Amgen focusing on innovative therapies. As awareness of diverticular disease grows, the market is set to expand, supported by favorable regulatory environments and increasing healthcare investments.

Middle East and Africa : Emerging Market with Challenges

The Diverticular Disease market in the Middle East and Africa is valued at 60.0 million, reflecting a nascent but growing sector. The region faces challenges such as limited healthcare access and varying levels of awareness about gastrointestinal disorders. However, increasing investments in healthcare infrastructure and rising disposable incomes are expected to drive market growth in the coming years. Countries like South Africa and the UAE are at the forefront, with efforts to improve healthcare services and access to treatments. The competitive landscape is characterized by a mix of local and international players, striving to address the unique healthcare needs of the region. As awareness and access improve, the market is likely to see significant growth, supported by ongoing regulatory reforms.

Key Players and Competitive Insights

The Diverticular Disease Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AbbVie (US), Johnson & Johnson (US), and Merck & Co. (US) are actively engaged in enhancing their product portfolios and expanding their market reach. AbbVie (US) has positioned itself as a leader in biologics, focusing on developing targeted therapies that address the underlying mechanisms of diverticular disease. Meanwhile, Johnson & Johnson (US) emphasizes a diversified approach, leveraging its extensive research capabilities to innovate in surgical solutions and minimally invasive techniques. Merck & Co. (US) appears to be concentrating on digital health initiatives, integrating technology into treatment protocols to improve patient outcomes and adherence.The business tactics employed by these companies reflect a commitment to optimizing supply chains and localizing manufacturing to enhance responsiveness to market demands. The competitive structure of the market is moderately fragmented, with several players vying for market share. However, the collective influence of these key players is significant, as they drive advancements in treatment options and patient care strategies, thereby shaping the overall market dynamics.

In November AbbVie (US) announced a strategic partnership with a leading telehealth provider to enhance patient access to its therapies for diverticular disease. This collaboration is expected to facilitate remote monitoring and personalized treatment plans, thereby improving patient engagement and adherence. Such initiatives underscore AbbVie's commitment to integrating technology into its therapeutic offerings, potentially setting a new standard for patient care in this domain.

In October Johnson & Johnson (US) launched a new minimally invasive surgical device aimed at treating diverticular disease. This innovation not only reflects the company's dedication to advancing surgical techniques but also positions it competitively against traditional surgical methods. The introduction of this device is likely to attract healthcare providers seeking to improve patient recovery times and reduce hospital stays, thereby enhancing overall treatment efficiency.

In September Merck & Co. (US) unveiled a digital health platform designed to support patients with diverticular disease in managing their condition. This platform incorporates AI-driven analytics to provide personalized insights and recommendations, which may significantly enhance patient engagement and treatment adherence. By investing in digital health solutions, Merck is likely to differentiate itself in a crowded market, appealing to a tech-savvy patient demographic.

As of December the competitive trends in the Diverticular Disease Market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient outcomes. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately redefine how companies position themselves in the market, emphasizing the importance of delivering value through enhanced patient care and innovative treatment solutions.

Key Companies in the Diverticular Disease Market include

Industry Developments

    • In January, Emmaus Life Sciences has announced the results to be under the preliminary focus. It has been observed the first patient with the company focus has attempted to make the study of the diverticulitis treatment (2020).
    • In 2020, May, Hikma Pharmaceuticals PLC. has launched the Dicyclomine Hydrochloride oral solution for the better treatment of the various inflammatory diagnosis of bowel diseases.

 

Future Outlook

Diverticular Disease Market Future Outlook

The Diverticular Disease Market is projected to grow at a 7.86% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising awareness.

New opportunities lie in:

  • Development of personalized dietary management programs
  • Investment in telehealth platforms for remote patient monitoring
  • Expansion of minimally invasive surgical techniques and technologies

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient engagement.

Market Segmentation

Diverticular Disease Market Disease Type Outlook

  • Diverticulitis
  • Diverticulosis
  • Diverticular Bleeding

Diverticular Disease Market Treatment Type Outlook

  • Medication
  • Surgery
  • Dietary Management
  • Lifestyle Changes

Diverticular Disease Market Diagnosis Method Outlook

  • Colonoscopy
  • CT Scan
  • Ultrasound
  • MRI

Diverticular Disease Market Patient Demographics Outlook

  • Age Group
  • Gender
  • Socioeconomic Status

Report Scope

MARKET SIZE 2024 1660.26(USD Million)
MARKET SIZE 2025 1809.78(USD Million)
MARKET SIZE 2035 3832.62(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.86% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled AbbVie (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Merck & Co. (US), Pfizer (US), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (JP), AstraZeneca (GB)
Segments Covered Disease Type, Treatment Type, Patient Demographics, Diagnosis Method
Key Market Opportunities Advancements in minimally invasive surgical techniques enhance treatment options in the Diverticular Disease Market.
Key Market Dynamics Rising prevalence of diverticular disease drives demand for innovative treatment options and enhanced patient management strategies.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Diverticular Disease Market as of 2024?

The Diverticular Disease Market was valued at approximately 1660.26 USD Million in 2024.

What is the projected market valuation for the Diverticular Disease Market in 2035?

The market is projected to reach approximately 3832.62 USD Million by 2035.

What is the expected CAGR for the Diverticular Disease Market during the forecast period 2025 - 2035?

The expected CAGR for the Diverticular Disease Market during the forecast period 2025 - 2035 is 7.86%.

Which companies are considered key players in the Diverticular Disease Market?

Key players in the market include AbbVie, Bristol-Myers Squibb, Johnson &amp; Johnson, Merck &amp; Co., Pfizer, Amgen, Gilead Sciences, Takeda Pharmaceutical, and AstraZeneca.

How is the Diverticular Disease Market segmented by disease type?

The market is segmented by disease type into Diverticulitis, Diverticulosis, and Diverticular Bleeding, with valuations ranging from 600.0 to 1800.0 USD Million.

What are the treatment types available in the Diverticular Disease Market?

Treatment types include Medication, Surgery, Dietary Management, and Lifestyle Changes, with valuations from 260.26 to 1400.0 USD Million.

How does patient demographics influence the Diverticular Disease Market?

The market is segmented by patient demographics, including Age Group, Gender, and Socioeconomic Status, with valuations between 560.26 and 1400.0 USD Million.

What is the market performance based on severity levels of diverticular disease?

The market performance by severity level includes Mild, Moderate, and Severe cases, with valuations ranging from 499.12 to 1500.0 USD Million.

How does the healthcare setting impact the Diverticular Disease Market?

The market is segmented by healthcare setting into Outpatient, Inpatient, and Emergency Care, with valuations from 502.05 to 1500.0 USD Million.

What trends are expected in the Diverticular Disease Market by 2035?

By 2035, the Diverticular Disease Market is expected to grow significantly, driven by advancements in treatment options and increasing awareness.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Disease Type (USD Million)
    2. | | 4.1.1 Diverticulitis
    3. | | 4.1.2 Diverticulosis
    4. | | 4.1.3 Diverticular Bleeding
    5. | 4.2 Healthcare, BY Treatment Type (USD Million)
    6. | | 4.2.1 Medication
    7. | | 4.2.2 Surgery
    8. | | 4.2.3 Dietary Management
    9. | | 4.2.4 Lifestyle Changes
    10. | 4.3 Healthcare, BY Patient Demographics (USD Million)
    11. | | 4.3.1 Age Group
    12. | | 4.3.2 Gender
    13. | | 4.3.3 Socioeconomic Status
    14. | 4.4 Healthcare, BY Severity Level (USD Million)
    15. | | 4.4.1 Mild
    16. | | 4.4.2 Moderate
    17. | | 4.4.3 Severe
    18. | 4.5 Healthcare, BY Healthcare Setting (USD Million)
    19. | | 4.5.1 Outpatient
    20. | | 4.5.2 Inpatient
    21. | | 4.5.3 Emergency Care
    22. | 4.6 Healthcare, BY Region (USD Million)
    23. | | 4.6.1 North America
    24. | | | 4.6.1.1 US
    25. | | | 4.6.1.2 Canada
    26. | | 4.6.2 Europe
    27. | | | 4.6.2.1 Germany
    28. | | | 4.6.2.2 UK
    29. | | | 4.6.2.3 France
    30. | | | 4.6.2.4 Russia
    31. | | | 4.6.2.5 Italy
    32. | | | 4.6.2.6 Spain
    33. | | | 4.6.2.7 Rest of Europe
    34. | | 4.6.3 APAC
    35. | | | 4.6.3.1 China
    36. | | | 4.6.3.2 India
    37. | | | 4.6.3.3 Japan
    38. | | | 4.6.3.4 South Korea
    39. | | | 4.6.3.5 Malaysia
    40. | | | 4.6.3.6 Thailand
    41. | | | 4.6.3.7 Indonesia
    42. | | | 4.6.3.8 Rest of APAC
    43. | | 4.6.4 South America
    44. | | | 4.6.4.1 Brazil
    45. | | | 4.6.4.2 Mexico
    46. | | | 4.6.4.3 Argentina
    47. | | | 4.6.4.4 Rest of South America
    48. | | 4.6.5 MEA
    49. | | | 4.6.5.1 GCC Countries
    50. | | | 4.6.5.2 South Africa
    51. | | | 4.6.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 AbbVie (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Bristol-Myers Squibb (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Johnson & Johnson (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Merck & Co. (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Pfizer (US)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Amgen (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Gilead Sciences (US)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Takeda Pharmaceutical (JP)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 AstraZeneca (GB)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY DISEASE TYPE
    4. | 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
    5. | 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. | 6.6 US MARKET ANALYSIS BY SEVERITY LEVEL
    7. | 6.7 US MARKET ANALYSIS BY HEALTHCARE SETTING
    8. | 6.8 CANADA MARKET ANALYSIS BY DISEASE TYPE
    9. | 6.9 CANADA MARKET ANALYSIS BY TREATMENT TYPE
    10. | 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    11. | 6.11 CANADA MARKET ANALYSIS BY SEVERITY LEVEL
    12. | 6.12 CANADA MARKET ANALYSIS BY HEALTHCARE SETTING
    13. | 6.13 EUROPE MARKET ANALYSIS
    14. | 6.14 GERMANY MARKET ANALYSIS BY DISEASE TYPE
    15. | 6.15 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
    16. | 6.16 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    17. | 6.17 GERMANY MARKET ANALYSIS BY SEVERITY LEVEL
    18. | 6.18 GERMANY MARKET ANALYSIS BY HEALTHCARE SETTING
    19. | 6.19 UK MARKET ANALYSIS BY DISEASE TYPE
    20. | 6.20 UK MARKET ANALYSIS BY TREATMENT TYPE
    21. | 6.21 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    22. | 6.22 UK MARKET ANALYSIS BY SEVERITY LEVEL
    23. | 6.23 UK MARKET ANALYSIS BY HEALTHCARE SETTING
    24. | 6.24 FRANCE MARKET ANALYSIS BY DISEASE TYPE
    25. | 6.25 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
    26. | 6.26 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    27. | 6.27 FRANCE MARKET ANALYSIS BY SEVERITY LEVEL
    28. | 6.28 FRANCE MARKET ANALYSIS BY HEALTHCARE SETTING
    29. | 6.29 RUSSIA MARKET ANALYSIS BY DISEASE TYPE
    30. | 6.30 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
    31. | 6.31 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    32. | 6.32 RUSSIA MARKET ANALYSIS BY SEVERITY LEVEL
    33. | 6.33 RUSSIA MARKET ANALYSIS BY HEALTHCARE SETTING
    34. | 6.34 ITALY MARKET ANALYSIS BY DISEASE TYPE
    35. | 6.35 ITALY MARKET ANALYSIS BY TREATMENT TYPE
    36. | 6.36 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    37. | 6.37 ITALY MARKET ANALYSIS BY SEVERITY LEVEL
    38. | 6.38 ITALY MARKET ANALYSIS BY HEALTHCARE SETTING
    39. | 6.39 SPAIN MARKET ANALYSIS BY DISEASE TYPE
    40. | 6.40 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
    41. | 6.41 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    42. | 6.42 SPAIN MARKET ANALYSIS BY SEVERITY LEVEL
    43. | 6.43 SPAIN MARKET ANALYSIS BY HEALTHCARE SETTING
    44. | 6.44 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE
    45. | 6.45 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    46. | 6.46 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    47. | 6.47 REST OF EUROPE MARKET ANALYSIS BY SEVERITY LEVEL
    48. | 6.48 REST OF EUROPE MARKET ANALYSIS BY HEALTHCARE SETTING
    49. | 6.49 APAC MARKET ANALYSIS
    50. | 6.50 CHINA MARKET ANALYSIS BY DISEASE TYPE
    51. | 6.51 CHINA MARKET ANALYSIS BY TREATMENT TYPE
    52. | 6.52 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    53. | 6.53 CHINA MARKET ANALYSIS BY SEVERITY LEVEL
    54. | 6.54 CHINA MARKET ANALYSIS BY HEALTHCARE SETTING
    55. | 6.55 INDIA MARKET ANALYSIS BY DISEASE TYPE
    56. | 6.56 INDIA MARKET ANALYSIS BY TREATMENT TYPE
    57. | 6.57 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    58. | 6.58 INDIA MARKET ANALYSIS BY SEVERITY LEVEL
    59. | 6.59 INDIA MARKET ANALYSIS BY HEALTHCARE SETTING
    60. | 6.60 JAPAN MARKET ANALYSIS BY DISEASE TYPE
    61. | 6.61 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
    62. | 6.62 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    63. | 6.63 JAPAN MARKET ANALYSIS BY SEVERITY LEVEL
    64. | 6.64 JAPAN MARKET ANALYSIS BY HEALTHCARE SETTING
    65. | 6.65 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
    66. | 6.66 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    67. | 6.67 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    68. | 6.68 SOUTH KOREA MARKET ANALYSIS BY SEVERITY LEVEL
    69. | 6.69 SOUTH KOREA MARKET ANALYSIS BY HEALTHCARE SETTING
    70. | 6.70 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE
    71. | 6.71 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
    72. | 6.72 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    73. | 6.73 MALAYSIA MARKET ANALYSIS BY SEVERITY LEVEL
    74. | 6.74 MALAYSIA MARKET ANALYSIS BY HEALTHCARE SETTING
    75. | 6.75 THAILAND MARKET ANALYSIS BY DISEASE TYPE
    76. | 6.76 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
    77. | 6.77 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    78. | 6.78 THAILAND MARKET ANALYSIS BY SEVERITY LEVEL
    79. | 6.79 THAILAND MARKET ANALYSIS BY HEALTHCARE SETTING
    80. | 6.80 INDONESIA MARKET ANALYSIS BY DISEASE TYPE
    81. | 6.81 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
    82. | 6.82 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    83. | 6.83 INDONESIA MARKET ANALYSIS BY SEVERITY LEVEL
    84. | 6.84 INDONESIA MARKET ANALYSIS BY HEALTHCARE SETTING
    85. | 6.85 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE
    86. | 6.86 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
    87. | 6.87 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    88. | 6.88 REST OF APAC MARKET ANALYSIS BY SEVERITY LEVEL
    89. | 6.89 REST OF APAC MARKET ANALYSIS BY HEALTHCARE SETTING
    90. | 6.90 SOUTH AMERICA MARKET ANALYSIS
    91. | 6.91 BRAZIL MARKET ANALYSIS BY DISEASE TYPE
    92. | 6.92 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
    93. | 6.93 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    94. | 6.94 BRAZIL MARKET ANALYSIS BY SEVERITY LEVEL
    95. | 6.95 BRAZIL MARKET ANALYSIS BY HEALTHCARE SETTING
    96. | 6.96 MEXICO MARKET ANALYSIS BY DISEASE TYPE
    97. | 6.97 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
    98. | 6.98 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    99. | 6.99 MEXICO MARKET ANALYSIS BY SEVERITY LEVEL
    100. | 6.100 MEXICO MARKET ANALYSIS BY HEALTHCARE SETTING
    101. | 6.101 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE
    102. | 6.102 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
    103. | 6.103 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    104. | 6.104 ARGENTINA MARKET ANALYSIS BY SEVERITY LEVEL
    105. | 6.105 ARGENTINA MARKET ANALYSIS BY HEALTHCARE SETTING
    106. | 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE
    107. | 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    108. | 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    109. | 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY SEVERITY LEVEL
    110. | 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY HEALTHCARE SETTING
    111. | 6.111 MEA MARKET ANALYSIS
    112. | 6.112 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE
    113. | 6.113 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
    114. | 6.114 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    115. | 6.115 GCC COUNTRIES MARKET ANALYSIS BY SEVERITY LEVEL
    116. | 6.116 GCC COUNTRIES MARKET ANALYSIS BY HEALTHCARE SETTING
    117. | 6.117 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE
    118. | 6.118 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
    119. | 6.119 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    120. | 6.120 SOUTH AFRICA MARKET ANALYSIS BY SEVERITY LEVEL
    121. | 6.121 SOUTH AFRICA MARKET ANALYSIS BY HEALTHCARE SETTING
    122. | 6.122 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE
    123. | 6.123 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
    124. | 6.124 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    125. | 6.125 REST OF MEA MARKET ANALYSIS BY SEVERITY LEVEL
    126. | 6.126 REST OF MEA MARKET ANALYSIS BY HEALTHCARE SETTING
    127. | 6.127 KEY BUYING CRITERIA OF HEALTHCARE
    128. | 6.128 RESEARCH PROCESS OF MRFR
    129. | 6.129 DRO ANALYSIS OF HEALTHCARE
    130. | 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    131. | 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    132. | 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
    133. | 6.133 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE)
    134. | 6.134 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
    135. | 6.135 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    136. | 6.136 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    137. | 6.137 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    138. | 6.138 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    139. | 6.139 HEALTHCARE, BY SEVERITY LEVEL, 2024 (% SHARE)
    140. | 6.140 HEALTHCARE, BY SEVERITY LEVEL, 2024 TO 2035 (USD Million)
    141. | 6.141 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
    142. | 6.142 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
    143. | 6.143 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    5. | | 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    6. | | 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    7. | | 7.2.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    8. | | 7.2.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    9. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    10. | | 7.3.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    11. | | 7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    12. | | 7.3.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    13. | | 7.3.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    14. | | 7.3.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    15. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.4.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    17. | | 7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    18. | | 7.4.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    19. | | 7.4.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    20. | | 7.4.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    21. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    22. | | 7.5.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    23. | | 7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    24. | | 7.5.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    25. | | 7.5.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    26. | | 7.5.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    27. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.6.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    29. | | 7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    30. | | 7.6.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    31. | | 7.6.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    32. | | 7.6.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    33. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.7.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    35. | | 7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    36. | | 7.7.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    37. | | 7.7.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    38. | | 7.7.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    39. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.8.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    41. | | 7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    42. | | 7.8.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    43. | | 7.8.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    44. | | 7.8.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    45. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    46. | | 7.9.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    47. | | 7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    48. | | 7.9.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    49. | | 7.9.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    50. | | 7.9.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    51. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.10.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    53. | | 7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    54. | | 7.10.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    55. | | 7.10.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    56. | | 7.10.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    57. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    58. | | 7.11.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    59. | | 7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    60. | | 7.11.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    61. | | 7.11.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    62. | | 7.11.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    63. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.12.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    65. | | 7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    66. | | 7.12.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    67. | | 7.12.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    68. | | 7.12.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    69. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    70. | | 7.13.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    71. | | 7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    72. | | 7.13.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    73. | | 7.13.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    74. | | 7.13.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    75. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.14.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    77. | | 7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    78. | | 7.14.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    79. | | 7.14.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    80. | | 7.14.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    81. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    82. | | 7.15.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    83. | | 7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    84. | | 7.15.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    85. | | 7.15.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    86. | | 7.15.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    87. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.16.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    89. | | 7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    90. | | 7.16.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    91. | | 7.16.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    92. | | 7.16.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    93. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.17.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    95. | | 7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    96. | | 7.17.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    97. | | 7.17.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    98. | | 7.17.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    99. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.18.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    101. | | 7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    102. | | 7.18.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    103. | | 7.18.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    104. | | 7.18.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    105. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    106. | | 7.19.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    107. | | 7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    108. | | 7.19.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    109. | | 7.19.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    110. | | 7.19.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    111. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.20.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    113. | | 7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    114. | | 7.20.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    115. | | 7.20.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    116. | | 7.20.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    117. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    118. | | 7.21.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    119. | | 7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    120. | | 7.21.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    121. | | 7.21.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    122. | | 7.21.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    123. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.22.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    125. | | 7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    126. | | 7.22.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    127. | | 7.22.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    128. | | 7.22.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    129. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    130. | | 7.23.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    131. | | 7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    132. | | 7.23.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    133. | | 7.23.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    134. | | 7.23.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    135. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    136. | | 7.24.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    137. | | 7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    138. | | 7.24.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    139. | | 7.24.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    140. | | 7.24.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    141. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    142. | | 7.25.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    143. | | 7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    144. | | 7.25.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    145. | | 7.25.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    146. | | 7.25.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    147. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    148. | | 7.26.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    149. | | 7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    150. | | 7.26.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    151. | | 7.26.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    152. | | 7.26.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    153. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    154. | | 7.27.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    155. | | 7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    156. | | 7.27.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    157. | | 7.27.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    158. | | 7.27.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    159. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    160. | | 7.28.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    161. | | 7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    162. | | 7.28.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    163. | | 7.28.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    164. | | 7.28.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    165. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    166. | | 7.29.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    167. | | 7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    168. | | 7.29.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    169. | | 7.29.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    170. | | 7.29.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    171. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    172. | | 7.30.1 BY DISEASE TYPE, 2025-2035 (USD Million)
    173. | | 7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    174. | | 7.30.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    175. | | 7.30.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    176. | | 7.30.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    177. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    178. | | 7.31.1
    179. | 7.32 ACQUISITION/PARTNERSHIP
    180. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Disease Type (USD Million, 2025-2035)

  • Diverticulitis
  • Diverticulosis
  • Diverticular Bleeding

Healthcare By Treatment Type (USD Million, 2025-2035)

  • Medication
  • Surgery
  • Dietary Management
  • Lifestyle Changes

Healthcare By Patient Demographics (USD Million, 2025-2035)

  • Age Group
  • Gender
  • Socioeconomic Status

Healthcare By Severity Level (USD Million, 2025-2035)

  • Mild
  • Moderate
  • Severe

Healthcare By Healthcare Setting (USD Million, 2025-2035)

  • Outpatient
  • Inpatient
  • Emergency Care
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓